Table E1.
Cohort demographics and clinical characteristics
| Patients with early RA | Patients with established RA | Patients with established SLE | Healthy control subjects | Difference between groups | |
|---|---|---|---|---|---|
| No. | 50 | 25 | 23 | 23 | — |
| Age (y), median (range) | 57.5 (30-91) | 67.5 (28-81) | 55 (33-69) | 36.5 (25-62) | P < .0001∗ |
| Male/female ratio | 2:3 | 2:3 | 1:8 | 1:1 | P < .0001∗ |
| Disease duration (y), median (range) | — | 10 (1-22) | 10 (1-35) | — | — |
| DAS28 score, median (range) | 4.36 (1.33-7.63) | 5.25 (2.6-8.43) | — | — | P = .104† |
| CRP (mg/L), median (range) | 7.5 (0-114) | 8 (0-96) | 5 (0-38) | — | P = .135∗ |
| ESR (mm/h), median (range) | 22.5 (2-68) | 25 (2-61) | 27 (5-109) | — | P = .381∗ |
| RF+ and/or anti-CCP+, no. (%) | 36 (72) | 20 (87) | — | — | P = .235‡ |
| Patients receiving oral DMARDs, no. (%)§ | 0 | 21 (91) | 20 (87) | — | — |
| Patients receiving biological DMARDs, no. (%)§ | 0 | 0 (0) | 0 (0) | — | |
| Patients receiving glucocorticoids, no. (%)§ | 0 | 3 (13) | 6 (26) | — | — |
| Early RA only | |||||
| Tender joint count, median (range) | 4 (0-25) | ||||
| Swollen joint count, median (range) | 2 (1-24) | ||||
| Patient VAS score, median (range) | 57 (8-100) | ||||
| Duration of symptoms (wk), median (range) | 12 (3-52) | ||||
| Early morning stiffness (min), median (range) | 52.5 (0-380) | ||||
Data are expressed as medians (ranges) or numbers (percentages). Notably, there was no significant differences between early and established RA for age and sex (P > .2, Tukey post hoc multiple comparison test).
anti-CCP, Anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; VAS, visual analog scale.
∗
One-way ANOVA.
†
Mann-Whitney U test.
‡
χ2 Test.
§
Drug history data were recorded at the time of baseline IGS measurement.